High blood pressure, headache, heavy sweating, rapid heartbeat, etc are some major symptoms of the pheochromocytomas. Pheochromocytomas is noncancerous tumor that develops in specialized cells, called chromaffin cells, located in the center of an adrenal gland.
|Analysis Period||2017 - 2028|
|Forecast Data||2021 - 2028|
|Segments Covered||By Diagnosis, By Treatment, By Application and By Geography|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||Exelixis, Inc., MediaPharma s.r.l., Pfizer Inc., Progenics Pharmaceuticals, Inc., and Valeant Pharmaceuticals International, Inc.|
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
|Customization Scope||10 hrs of free customization and expert consultation|
Prevalence of Pheochromocytoma tumor is witnessed across the globe. It is a rare type of tumor that originates from the chromaffin cells that are responsible for the production of necessary hormones for the body function properly. Pheochromocytoma generally is witnessed on the adrenal gland which is located above the kidney. Adrenal medulla contains major amount of chromaffin cells they can be seen in the adrenal glands inner layer. Approximately 90 percent of pheochromocytomas occur in the adrenal medulla. Approximately 10 percent occur outside of this area. Rise in number of patients suffering from chronic tumor across the globe and rapid advancements in the healthcare sector are major factors expected to drive the growth of global pheochromocytoma market. In the United States, about 2 to 8 people per every 1 million people are diagnosed with these tumors each year. Around 100 to 200 of these cases are malignant. In Europe a total of 239 patients with pheochromocytoma or paraganglioma (collectively with 251 tumors) were identified from a population of 5 196 368 people over a period of 7 years. The overall incidence of pheochromocytoma or paraganglioma was 0.66 cases per 100 000 people per year.
Drugs manufacturers are investing high for the development of new drugs, high flow of clinical trials and favorable policies by the government are factors expected to augment the growth of pheochromocytoma market.
In 2019, Ono Pharmaceutical Co. Ltd., a global drug manufacturer launched “Demser” Capsule 250 mg a tyrosine hydroxylase inhibitor for the improvement of status of catecholamine excess secretion in pheochromocytoma in Japan market. This product launch is expected to help the company to enhance the business and increase the revenue share.
In 2018, U.S. Food and Drug Administration approved “Azedra” an injection made by Progenics Pharmaceuticals, Inc. in the US market. The injection is for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland. This is expected to help the company to enhance the business and increase the revenue share in the market.
Major players approach towards enhancing the business in emerging economies through partnerships and shift the manufacturing units to developing countries due to easy availability of raw material and low cost labor these factors are expected to boost the growth of target market. Factors such as high cost associated to drug development and lack of developed infrastructure for R&D activities in developing countries are expected to hamper the growth of global pheochromocytoma market. In addition, strict regulation by the government for product approval is expected to challenge the growth of target market. However, increasing investment for R&D activities and collaborative work approach for drug development are factors expected to create new opportunities for players operating in the pheochromocytoma market over the forecast period. In addition, increasing acquisition activities by major players in order to strengthen its customer base and enhance the product offerings is expected to support the revenue transaction of the target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global pheochromocytoma market due to high patient pool suffering from chronic diseases. Presence of large number of players operating in the country and introduction of new drugs is expected to augment the growth of pheochromocytoma market. Increasing acquisition activities by major players in order to enhance the business and increase the product portfolio is expected to support the region market growth.
The global pheochromocytoma market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Pheochromocytoma Market Segment Analysis, 2019
The global pheochromocytoma market is segmented into diagnosis and treatment. The diagnosis segment is divided into laboratory tests, imaging tests, and genetic testing. The treatment segment is bifurcated into medications and surgery. Among treatment the medication segment is expected to account for major revenue share in the global pheochromocytoma market. The players profiled in the report are Exelixis, Inc., MediaPharma s.r.l., Pfizer Inc., Progenics Pharmaceuticals, Inc., and Valeant Pharmaceuticals International, Inc.
Market By Diagnosis
Market By Treatment
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
Rise in number of patients suffering from chronic tumor across the globe and rapid advancements in the healthcare sector are major factors expected to drive the growth of global pheochromocytoma market.
In diagnosis the laboratory tests segment is growing at faster pace.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Exelixis, Inc., MediaPharma s.r.l., Pfizer Inc., and Progenics Pharmaceuticals, Inc.
The North America is expected to account for major revenue share in the global market.
Factors such as high cost associated to drug development and lack of developed infrastructure for R&D activities in developing countries are expected to hamper the growth of global pheochromocytoma market.